Preventing the Exhaustion of T Cells11/02/2023
In the immune system's fight against cancer and infections, the T cells often lose their power. The team of Würzburg immunologist Martin Vaeth has found a possible explanation for this phenomenon.
In the immune system, chronic infections and the defence against tumors often lead to the phenomenon of T cell exhaustion: In this process, the T lymphocytes gradually lose their function, which impairs their responses against cancer and infections. The molecular mechanisms that control this loss of function have not been fully unraveled.
It is now certain that the exhaustion process is significantly influenced by the “powerhouses of the cells”, the mitochondria.
When mitochondrial respiration fails, a cascade of reactions is triggered, culminating in the genetic and metabolic reprogramming of T cells – a process that drives their functional exhaustion. But this "burnout" of the T cells can be counteracted: pharmacological or genetic optimization of cellular metabolism increases the longevity and functionality of T cells. This can be achieved, for example, by overexpressing a mitochondrial phosphate transporter that drives the production of the energy-providing molecule adenosine-triphosphate.
These discoveries are reported by a team led by Dr. Martin Vaeth at the Institute for Systems Immunology at Julius-Maximilians-Universität (JMU) Würzburg in the journal Nature Communications. "We are optimistic that our findings will contribute to the improvement of cancer immunotherapy", the scientist says.
Possible Improvement of CAR-T Cell Therapy
One example: CAR-T cell therapy has demonstrated remarkable efficacy in the treatment of leukemia and lymphoma. CAR-T cells are lymphocytes that that have been engineered in the laboratory to fight the respective form of cancer. However, when it comes to solid tumors, CAR-T cells also tend to exhaustion, limiting their success in this context.
"Our experiments demonstrate that augmented mitochondrial metabolism also increases the longevity and functionality of virus-specific T cells in chronic infections," says the JMU scientist. It is plausible that this strategy can be also harnessed to enhance T-cell-based immunotherapies for cancer therapy.
The Experiments in Detail
"It was commonly assumed that the observed alterations in the mitochondrial (energy) metabolism were a consequence of T-cell exhaustion," says Vaeth. To demonstrate that mitochondrial dysfunction is the actual cause of T cell exhaustion, his research group developed a new genetic model. It switches off the mitochondrial phosphate transporter (SLC25A3) and paralyses mitochondrial respiration in T cells.
As a result, the T cells are forced to switch to alternative metabolic pathways, mainly aerobic glycolysis, to meet their bioenergetic demand in the form of adenosine triphosphate. However, this metabolic adaptation causes an increased production of reactive oxygen species in the T cells.
Elevated levels of oxygen radicals prevent the degradation of the transcription factor hypoxia-inducible factor 1 alpha (HIF-1-alpha). The accumulation of HIF-1-alpha protein causes a genetic and metabolic reprogramming of the T cells, accelerating their exhaustion.
"This HIF-1-alpha-dependent control of T-cell exhaustion was previously unknown. It represents a critical regulatory circuit between mitochondrial respiration and T cell function, serving as a 'metabolic checkpoint' in the process of T-cell exhaustion", explains Vaeth.
Considering Tissue as the Environment of T Cells
Next, his team wants to explore how mitochondrial respiration influences the epigenetic programming of T cells, for example through post-translational modifications of histones, and the interplay of T-cell metabolism with the local tissue microenvironment.
According to Martin Vaeth, this is particularly important because the nutrient supply and oxygen tension in tumors differ considerably from healthy tissue and T cells must actively respond to this challenging environment. New technical developments, such as spatial transcriptome and metabolome analyses, offer exciting new possibility to investigate these questions systematically and at high resolution in the context of the tissue microenvironment.
Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming. Nature Communications 14, 6858 (2023), DOI 10.1038/s41467-023-42634-3.
Open Access: https://www.nature.com/articles/s41467-023-42634-3
Most of the work described was carried out in Martin Vaeth's laboratory. The metabolic analyses were performed by Professor Bart Ghesquière at the Catholic University of Leuven (Belgium). The single-cell sequencing analyses were done in cooperation with the Single-Cell Centre of the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg.
The study was supported by the German Research Foundation (DFG) within the framework of the Transregio 338 "Lymphocyte engineering for therapeutic synthetic immunity" (Würzburg-Munich) and the Collaborative Research Centre 1525 "Cardio-immune interfaces" (Würzburg).
Dr. Martin Vaeth, head of a research group at the Max Planck Research Group for Systems Immunology, University of Würzburg, T +49 931 31-82491, firstname.lastname@example.org
Immunology in Würzburg
The Würzburg University Medical Center is a distinguished research institution in the field of immunology and has greatly expanded its expertise in recent years. Across numerous institutes and academic chairs, scientists exploring the intricacies of the immune system, harnessing this knowledge to fight diseases. This collaborative effort also involves other researchers not only in Germany but also across the globe.
Research Alliance Immunomedicine
The University of Würzburg is part of the research alliance immunomedicine (Forschungsallianz Immunmedizin). The aim of this alliance is the development of new diagnostic tools and therapies for major common diseases such as infections, cancer and autoimmune diseases. The alliance networks complementary strategies of the University sites Erlangen-Nürnberg, Regensburg and Würzburg and develops synergistic key areas to strengthen immunomedicine at the highest level in northern and eastern Bavaria.